Really important paper in print today by Adam Sperling, MD, PhD and colleagues on Revlimid and p53 mutations that cause therapy-related myeloid neoplasms ashpublications.org/blood/article-…

An agenda to advance research in MDS: A TOP 10 Priority List from the first international workshop in MDS (iwMDS) Congrats to Maximilian Stahl Amer Zeidan MBBS,MHS ‏عامر زيدان & the rest of our #iwMDS team Blood Advances #mdssm pubmed.ncbi.nlm.nih.gov/36260702/

BULLS WIN.
BULLS WIN.
BULLS WIN.
BULLS WIN.
BULLS WIN.

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals #bmtsm #lymsm #immunotherapy ashpublications.org/blood/article-…

So excited to hear my co-chief and friend Alexandra Goodwin speak about telehealth at Landsberg Society Weekend Update #landsbergsociety #weekendupdate

In the era of several frontline InO trials, our report provides some evidence for INO re-tx for pts w/ CD22+ dz Of note, our pts had specific characteristics: response to INO1, previous tx w/ chemo-based regimens, prior CD19 tx or lack of CD19, & strong CD22 expression pre-INO2.

Median OS from INO2 was not reached at time of data lock (median follow-up 16.5 months). VOD was seen one of 6 pts that received InO and it occurred after a 2nd allo-SCT for that pt.

Patients rec’d InO re-tx a median of 2.3 years after initial InO. After re-treatment 5 pt achieved CR and 1 pt achieved PR. All pt had strong CD22+ expression prior to initial InO (INO1) and InO re-treatment (INO2). The swimmer’s plot summarizes other tx received betw INO1 & INO2

We identified 6 pts at our center that received InO for R/R B-ALL and were subsequently re-treated for relapse/progression of CD22+ disease. Characteristics are summarized in the below tables. 5 of 6 pts had a CR to the 1st treatment with InO and 1 pt had a PR.

Median overall survival in adults with relapsed B-ALL is quite poor, particularly in those already treated with blinatumomab and/or InO. There is little published data about the utility of re-treatment with these drugs.

Very grateful for the chance to speak about MPNs at Landsberg Society Weekend Update with an audience of NU Internal Medicine alums and current trainees! Also got to highlight the impact my mentors have had on my career thus far! #mpnsm #weekendupdate

I'm a huge fan and have benefited so much from what Travis Zack has built with cpcuniverse, so it was an honor and joy to get to write this piece alongside a great mentor and colleague, Jeff Kohlwes.

link.springer.com/article/10.100…